Skip to main content
VCRE
NASDAQ Life Sciences

Vicore Q3 Loss Widens to SEK 124.3M; Cash of SEK 772M Funds Runway Into H2 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$10.01
Mkt Cap
$265.073M
52W Low
$7.88
52W High
$17.8
52W Position info
27% above low
Off High info
44% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

VCRE sits 27% above its 52-week low of $7.88.

Summary

Vicore's Q3 operating loss widened to SEK 133.3M while cash fell to SEK 772.0M, which management says funds operations into the second half of 2028, past the mid-2027 ASPIRE readout.


Key Events · Earnings and Guidance · VCRE

  • Q3 Loss Widens on ASPIRE Spending

    Operating loss was SEK 133.3M for Jul-Sep 2026 versus SEK 116.0M a year earlier; for the nine months it reached SEK 418.7M against SEK 318.7M in 2025.

  • Cash Falls to SEK 772.0M

    At September 30, 2026, cash, cash equivalents and short-term investments stood at SEK 772.0M (USD 77.4M), down from SEK 1,166.7M at December 31, 2025, after SEK 137.5M of Q3 operating cash burn.

  • Runway Extends Into H2 2028

    Management states the anticipated cash runway continues into the second half of 2028, funding the company well beyond the expected mid-2027 ASPIRE readout.

  • ASPIRE Topline Now Mid-2027

    Enrollment completed in April; after its pre-planned futility analysis, the iDMC recommended the Phase 2b IPF trial continue without modification, with topline results expected mid-2027.


Analysis · VCRE · Life Sciences

Cash, not the loss, is the quarter's headline. Operations consumed SEK 137.5M in Q3, leaving SEK 772.0M (USD 77.4M) in cash and short-term investments at September's end, down from SEK 1,166.7M at the start of the year. Management now says that funds the company into the second half of 2028, comfortably past the mid-2027 ASPIRE topline readout, so no financing overhang hangs over the trial result. As Phase 2b IPF study and Phase 3 preparation costs ramp, the operating loss widened to SEK 133.3M from SEK 116.0M a year earlier, and R&D still consumes 78.8% of operating expenses. The ASPIRE futility-analysis pass was already announced on October 22, so the incremental news here is financial: a funded balance sheet and a readout date pushed into mid-2027.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VCRE was trading at $10.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.1M. The 52-week trading range was $7.88 to $17.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VCRE - Latest Insights

VCRE
Oct 22, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.51
Real-time Price: $10.01 info
Change: -$0.500 (-5%) info
Market Cap: $265.073M info
VCRE
Aug 21, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.50
Real-time Price: $10.01 info
Change: -$2.49 (-20%) info
Market Cap: $265.073M info
VCRE
Jul 06, 2026, 9:16 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.53
Real-time Price: $10.01 info
Change: -$6.52 (-39%) info
Market Cap: $265.073M info